Document Detail

Antagonism between curcumin and the topoisomerase II inhibitor etoposide: a study of DNA damage, cell cycle regulation and death pathways.
MedLine Citation:
PMID:  22895066     Owner:  NLM     Status:  MEDLINE    
CONCLUSIONS: Cotreatment with ETP and CUR resulted in an antagonistic interaction. This antagonism is related, in part, to the enhanced arrest of tumor cells in both S and G 2/M phases, which prevents the cells from entering M-phase with damaged DNA and, consequently, prevents cell death from occurring. This arrest allows time for the cells to repair DNA damage so that cell cycle -arrested cells can eventually resume cell cycle progression and continue their physiological program.
Ekram M Saleh; Raafat A El-awady; Nadia A Eissa; Wael M Abdel-Rahman
Related Documents :
22578626 - Incidence of apoptosis and transcript abundance in bovine follicular cells is associate...
22311706 - The aryl hydrocarbon receptor contributes to the proliferation of human medulloblastoma...
15353546 - Robust cell polarity is a dynamic state established by coupling transport and gtpase si...
12955856 - Morphogenesis and dysmorphogenesis of the appendicular skeleton.
19942286 - Genetically engineered angiogenic cell sheets using magnetic force-based gene delivery ...
8392316 - Metabolic and morphological changes in a. albopictus cells infected with mayaro virus u...
Publication Detail:
Type:  Journal Article     Date:  2012-08-16
Journal Detail:
Title:  Cancer biology & therapy     Volume:  13     ISSN:  1555-8576     ISO Abbreviation:  Cancer Biol. Ther.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-12     Completed Date:  2013-04-11     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  101137842     Medline TA:  Cancer Biol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1058-71     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Phytogenic / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Cell Cycle / drug effects*
Cell Death / drug effects
Cell Line, Tumor
Curcumin / pharmacology*
DNA Damage*
Drug Interactions
Etoposide / pharmacology*
HCT116 Cells
HeLa Cells
Hep G2 Cells
MCF-7 Cells
Taurine / pharmacology
Topoisomerase II Inhibitors / pharmacology*
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Topoisomerase II Inhibitors; 1EQV5MLY3D/Taurine; 6PLQ3CP4P3/Etoposide; IT942ZTH98/Curcumin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1? expression by block...
Next Document:  Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cance...